CD274 and neoplasm: Although the administration of anti-PD-L1 antibodies alone had a moderate therapeutic effect, the addition of PD-1 blockade to the B-cell vaccines significantly reduced the median tumor growth rate compared to the non-combined groups, but no tumor rejections were observed.